Table 7

Correlations between VEGF-C expression and clinicopathological characteristics

Clinicopathological characteristics

N

VEGF-C positive

P

VEGF-C mRNA expression level

P


N

rate (%)


Age (years)

<60

30

23

76.7

2.41 ± 0.33

≥ 60

11

10

90.9

0.412

3.20 ± 0.76

0.505

Histological grade

(invasive ductal)

I+II

16

14

87.5

2.72 ± 0.58

III+IV

20

14

70.0

0.257

2.65 ± 0.45

0.908

Tumor size

T1

15

12

80.0

3.00 ± 0.63

T2

23

18

78.3

2.14 ± 0.31

T3

3

3

100

0.670

4.58 ± 1.68

0.237

Lymph nodal status

N0

22

20

90.9

2.92 ± 0.48

N1

12

8

66.7

2.10 ± 0.53

N2

5

3

60.0

2.51 ± 0.86

N3

2

2

100

0.606

2.65 ± 0.07

0.710

Estrogen receptor status

-

10

9

90.0

2.42 ± 0.63

+~+++

31

24

77.4

0.653

2.69 ± 0.38

0.606

Progesterone receptor status

-

8

6

75.0

2.14 ± 0.75

+~+++

33

27

81.8

0.642

2.75 ± 0.35

0.217

HER2/neu score

- (0-1)

13

10

76.9

2.70 ± 0.66

+ (2-3)

28

23

82.1

0.693

2.60 ± 0.36

0.918


"+", "++" and "+++" for VEGF-C immunochemistry staining was all grouped together as "+"

Wu et al. BMC Cancer 2012 12:47   doi:10.1186/1471-2407-12-47

Open Data